Moleculin Biotech, Inc. · NASDAQ:MBRX

Moleculin Biotech — Investor Presentation (September 2016)

21 slides from Moleculin Biotech's investor presentation, Sep 12, 2016

  1. Slide 1: August 2016

    August 2016

  2. Slide 2: Disclaimer

    Disclaimer All statements contained herein other than statements of historical fact, including statements regarding our future results of operations and financial position, our business strategy and plans, and our objectives for future operations, are forward-looking statements. The words “believe,”

  3. Slide 3: Diverse portfolio of disruptive cancer technologies

    We built Moleculin around a diverse portfolio of disruptive cancer technologies, each with high revenue potential. Our lead leukemia drug candidate has already shown life-saving potential in clinical trials. We have a unique compound that appears to both attack the most difficult cancers directly wh

  4. Slide 4: Moleculin Team

    Moleculin Team

  5. Slide 5: Veteran Management Team

    Veteran Management Team Cisplatin Carboplatin COO Harvard, Tufts, UVA Dana Farber, FDA #1 INC 500 List $400 million in revenue CMO CEO

  6. Slide 6: Advisors and Board Members

    Advisors and Board Members Reata Pharmaceuticals Big 4 audit partners Multi-billion dollar exit Cancer experts

  7. Slide 7: Technologies developed at MD Anderson Cancer Center

    All of our technologies were developed at MD Anderson Cancer Center, the world’s largest cancer research facility headquartered within the world’s largest medical center With over 1,500 cancer researchers, our sponsored research has been supported by truly state of the art resources

  8. Slide 8: Technology Portfolio

    Technology Portfolio

  9. Slide 9: Technology pipeline by development stage

    Discovery (Finding potential new drugs) Pre-Clinical Development (Laboratory Testing) IND Filing (Investigational New Drug; FDA Filing) Phase I/II (Human safety & proof of concept) Approval Trial (Phase IIb or III as required) Adult AML WP1066 (Glioblastoma, metastatic melanoma) WP1122 (Glioblastoma

  10. Slide 10: Annamycin

    Annamycin

  11. Slide 11: Moleculin

    ® Moleculin

  12. Slide 12: Induction therapy and bone marrow transplant success rates

    BMT (Results in Cure) 20% 80% Success Failure Induc4on Therapy (Qualify for BMT) 80% 20% Success Failure

  13. Slide 13: Annamycin vs current drugs

    Non-cardiotoxic Avoids multidrug resistance More potent Cardiotoxic Defeated by multidrug resistance Current Drugs Annamycin

  14. Slide 14: Doxorubicin Example

    Doxorubicin Example

  15. Slide 15: Annamycin Example

    Annamycin Example

  16. Slide 16: Annamycin Delivers Relapsed/Refractory Acute Leukemia Patients

    Annamycin Delivers Relapsed/Refractory Acute Leukemia Patients 50% Efficacy Signal 30% Cleared Bone Marrow Blasts Annamycin gives new hope to patients who have run out of options Patients failed an average of 5 previous Induction Therapy attempts with standard of care

  17. Slide 17: What is possible if we get to patients sooner?

    Annamycin (based on last trial) What is possible if we get to patients sooner?

  18. Slide 18: WP1066

    WP1066 Directly attacks the worst cancers Recruits natural immune system IRB approved for human trial

  19. Slide 19: WP1122

    WP1122 Cuts off fuel supply to brain tumors Outperforms billion-dollar drug Human trials in 1-2 years

  20. Slide 20: We Are Excited

    a ——SCSC‘C;SCsC(‘( We Are Excited ~ ® Moleculin

  21. Slide 21: Investment Highlights

    Investment Highlights Multiple shots Worldclass collaboration Game-changing breakthroughs Solid protection Veteran management

Moleculin Biotech — Investor Presentation (September 2016) on 6ix